86 related articles for article (PubMed ID: 2804301)
1. [Characteristics of the action of cisplatin and cycloplatam on the rat kidney].
Natochin IuV; Reznik LV; Brovtsyn VK; Ivanov VB; Miazina EM; Chel'tsov PA; Shakhmatova EI
Biull Eksp Biol Med; 1989 Jul; 108(7):52-4. PubMed ID: 2804301
[TBL] [Abstract][Full Text] [Related]
2. [Comparative study of the action of antineoplastic platinum compounds with varying nephrotoxic effects].
Bakhteeva VT; Fok EM; Lavrova EA
Vopr Med Khim; 1996; 42(4):301-6. PubMed ID: 9254514
[TBL] [Abstract][Full Text] [Related]
3. [Effect of anti-tumor agents cisplatin and cycloplatam on membrane protein kinase C activity in murine T-lymphocytes].
Khabarov SV; Gerasimova GK
Biokhimiia; 1996 Oct; 61(10):1866-73. PubMed ID: 9011234
[TBL] [Abstract][Full Text] [Related]
4. Experimental study of renal disorder caused by oxaliplatin in rat renal cortical slices.
Kanou T; Uozumi J; Soejima K; Tokuda Y; Masaki Z
Clin Exp Nephrol; 2004 Dec; 8(4):310-5. PubMed ID: 15619029
[TBL] [Abstract][Full Text] [Related]
5. [Morphofunctional correlates of the nephrotoxic action of cis-platin].
Bakhteeva VT; Vinnichenko LN; Gambarian SP; Miazina EM; Natochin IuV
Arkh Patol; 1987; 49(3):48-54. PubMed ID: 3593006
[TBL] [Abstract][Full Text] [Related]
6. Comparative nephrotoxicity of cisplatin and new octahedral Pt(IV) complexes.
Kim WK; Kwon YE
Cancer Chemother Pharmacol; 2007 Jul; 60(2):237-43. PubMed ID: 17089165
[TBL] [Abstract][Full Text] [Related]
7. [The use of prednisolone for the attenuation of the nephrotoxic effect of cisplatin].
Bakhteeva VT; Karpenko LA
Eksp Klin Farmakol; 1994; 57(4):55-8. PubMed ID: 7950789
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
9. Reversal of cisplatin-induced carnitine deficiency and energy starvation by propionyl-L-carnitine in rat kidney tissues.
Aleisa AM; Al-Majed AA; Al-Yahya AA; Al-Rejaie SS; Bakheet SA; Al-Shabanah OA; Sayed-Ahmed MM
Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1252-9. PubMed ID: 17973863
[TBL] [Abstract][Full Text] [Related]
10. Ontogenic aspects of cisplatin-induced nephrotoxicity in rats.
Ali BH; Al-Moundhri M; Tageldin M; Al Husseini IS; Mansour MA; Nemmar A; Tanira MO
Food Chem Toxicol; 2008 Nov; 46(11):3355-9. PubMed ID: 18790000
[TBL] [Abstract][Full Text] [Related]
11. Effect of oxoplatinum and CBDCA on renal functions in rats.
Láznícková A; Semecký V; Láznícek M; Zubr V; Koksál J; Kvĕtina J
Neoplasma; 1989; 36(2):161-9. PubMed ID: 2654665
[TBL] [Abstract][Full Text] [Related]
12. Magnesium depletion enhances cisplatin-induced nephrotoxicity.
Lajer H; Kristensen M; Hansen HH; Nielsen S; Frøkiaer J; Ostergaard LF; Christensen S; Daugaard G; Jonassen TE
Cancer Chemother Pharmacol; 2005 Nov; 56(5):535-42. PubMed ID: 15947931
[TBL] [Abstract][Full Text] [Related]
13. The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice.
Hirose A; Sato E; Fujii H; Sun B; Nishioka H; Aruoma OI
Toxicol Appl Pharmacol; 2007 Jul; 222(2):152-8. PubMed ID: 17555784
[TBL] [Abstract][Full Text] [Related]
14. Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats.
Uehara T; Watanabe H; Itoh F; Inoue S; Koshida H; Nakamura M; Yamate J; Maruyama T
Arch Toxicol; 2005 Aug; 79(8):451-60. PubMed ID: 15856183
[TBL] [Abstract][Full Text] [Related]
15. Transplacental passage of Pt after treatment with the new triamine complex cis-diaminechloro-[2-(diethylamino) ethyl 4-amino-benzoate, N4]-chloride platinum (II) monohydrochloride monohydrate.
Ognio E; Chiavarina B; Caviglioli G; Lapide M; Viale M
Arch Toxicol; 2004 Oct; 78(10):584-8. PubMed ID: 15150682
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of a palladium(II)-dithiocarbamate complex: biological assay and nephrotoxicity in rats.
Trevisan A; Marzano C; Cristofori P; Borella Venturini M; Giovagnini L; Fregona D
Arch Toxicol; 2002 Jun; 76(5-6):262-8. PubMed ID: 12107643
[TBL] [Abstract][Full Text] [Related]
17. [Biochemical mechanisms of resistance to a new antineoplastic agent amin(cyclopeptidylamin)-S-(-)-malatoplatinum (II) (cycloplatam)].
Dederer LIu; Lankin VZ; Konovalova AL; Gorbacheva LB
Biokhimiia; 1995 Apr; 60(4):602-9. PubMed ID: 7779982
[TBL] [Abstract][Full Text] [Related]
18. Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors.
Dominguez MF; Macias RI; Izco-Basurko I; de La Fuente A; Pascual MJ; Criado JM; Monte MJ; Yajeya J; Marin JJ
J Pharmacol Exp Ther; 2001 Jun; 297(3):1106-12. PubMed ID: 11356935
[TBL] [Abstract][Full Text] [Related]
19. Protective effects of L-arginine against cisplatin-induced renal oxidative stress and toxicity: role of nitric oxide.
Saleh S; El-Demerdash E
Basic Clin Pharmacol Toxicol; 2005 Aug; 97(2):91-7. PubMed ID: 15998355
[TBL] [Abstract][Full Text] [Related]
20. Effects of the anticancer dehydrotarplatin on cytochrome P450 and antioxidant enzymes in male rat tissues.
Nannelli A; Messina A; Marini S; Trasciatti S; Longo V; Gervasi PG
Arch Toxicol; 2007 Jul; 81(7):479-87. PubMed ID: 17364183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
